Tarsus Pharmaceuticals (TARS) Cash from Operations (2019 - 2026)

Tarsus Pharmaceuticals' Cash from Operations history runs 8 years deep, the most recent figure standing at 24652000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 19.37% year-over-year to 24652000.0; the TTM figure through Mar 2026 stood at 16452000.0 (up 75.03% YoY), while the FY2025 annual figure was 12451000.0, up 85.0% from the prior year.
• Cash from Operations was 24652000.0 for Q1 2026 at Tarsus Pharmaceuticals, down from 19330000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 19330000.0 in Q4 2025 to a low of 39335000.0 in Q4 2023.
• Historically, Cash from Operations has averaged 16861941.18 across 5 years, with a median of 20651000.0 in 2025.
• The sharpest annual moves came in 2023 and 2025: Cash from Operations sank 459.43% in 2023, then jumped 311.01% in 2025.
• A 5-year view of Cash from Operations shows it stood at 10874000.0 in 2022, then slumped by 261.73% to 39335000.0 in 2023, then soared by 43.61% to 22182000.0 in 2024, then surged by 187.14% to 19330000.0 in 2025, then sank by 227.53% to 24652000.0 in 2026.
• The last three Cash from Operations figures came in at 24652000.0 (Q1 2026), 19330000.0 (Q4 2025), and 18257000.0 (Q3 2025), per Business Quant data.